BLINCYTO Powder for Concentrate for Solution for Infusion
Blinatumomab
35 mcg
ACTAVIS ITALY S.P.A.
| Pack size | 1 Vial |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 9946.20 AED |
Indications
BLINCYTO Powder for Concentrate for Solution for Infusion is used for:
Indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Blinatumomab :
Mechanism of Action
Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. It activates endogenous T cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B cells. Blinatumomab mediates the formation of a synapse between the T cell and the tumor cell, upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T cells, which result in redirected lysis of CD19+ cells.
Note
BLINCYTO 35 mcg Powder for Concentrate for Solution for Infusion manufactured by ACTAVIS ITALY S.P.A.. Its generic name is Blinatumomab. BLINCYTO is availble in Saudi Arabia.
Farmaco SA drug index information on BLINCYTO Powder for Concentrate for Solution for Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.